PhRMA Launches Advertising and Public Affairs Initiative

Article

The organization launched its GOBOLDLY campaign to highlight the work of US biopharmaceutical companies.

On Jan. 23, 2017 the Pharmaceutical Research and Manufacturers of America (PhRMA) announced the launch of a multi-year advertising and public affairs initiative on behalf of US biopharmaceutical companies. The campaign is titled GOBOLDLY and will include national television, print, digital, radio and out-of-home advertising focused on highlighting the work of biopharmaceutical companies.

According to PhRMA, the ad campaign highlights revolutionary biopharmaceutical science. The first television advertisement in the campaign features the Dylan Thomas poem Do Not Go Gentle. In addition to paid advertising, the campaign will include public affairs activities to foster a national dialogue with researchers, caregivers, patients, and policymakers in forums around the country. These discussions will focus on what the new era in medicine means for patients and the health care system and the types of public policy solutions that are needed to sustain progress.

“Through partnerships and collaborations with other health care leaders, we will work to advance commonsense solutions that foster the continued development of new medicines, enhance the private marketplace and provide patients with access to the newest and most innovative treatments,” said Stephen J. Ubl, president and CEO of PhRMA, in a statement.

The campaign will include three distinct public affairs initiatives around the following core areas: bold advancements in science, value-driven health care, and public health. These efforts will officially kick off in February and March 2017.

Source: PhRMA

 

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content